Update on the management of polycystic ovary syndrome.
Journal Title: Pharmacological Reports - Year 2006, Vol 58, Issue 5
Abstract
Polycystic ovary syndrome (PCOS) is a common endocrine disorder that affects 5% to 10% of women in reproductive age. It is the most simply defined as the association of hyperandrogenism (diagnosed clinically and/or biochemically) with chronic anovulation in the absence of specific ovarian, adrenal and pituitary gland diseases. Recent studies have revealed that PCOS is associated with hyperinsulinemia and insulin resistance. Both of them have been shown to play a substantial role in the increased risk of the cardiovascular events. The new data concerning the pathogenesis and management of PCOS have changed its treatment strategy. The management of PCOS is complex and includes lifestyle modification combined with dietary-induced weight loss, oral contraceptives, clomiphene citrate, gonadotropins, antiandrogens and insulin-sensitizing agents. Women with PCOS, diagnosed and managed properly, can benefit from the reduction or even reversal of the reproductive and metabolic morbidities and from the reduction of the risk factors for cardiovascular disorders. In this article, we describe all these treatment options. Although both standard and novel therapies are discussed, this review focuses on the progress made in the recent years.
Authors and Affiliations
Robert Krysiak, Bogusław Okopień, Anna Gdula-Dymek, Zbigniew Herman
Keywords
Related Articles
- EP ID EP133912
- DOI -
- Views 122
- Downloads 0
Effect of two behavioral tests on corticosterone level in plasma of mice lacking the noradrenaline transporter.
In the present study, we investigated plasma corticosterone levels of genetically modified mice lacking noradrenaline transporter (NET(-/-)), in response to the forced swim test (FST) and tail suspension test (TST). FST...
Role of TLR ligands in epicutaneously induced contrasuppression.
Our previous work showed that epicutaneous (EC) immunization in mice with protein antigen (Ag) induced an Ag-independent unresponsiveness mediated by suppressor CD4(+)8(+) T cells (Ts), which inhibited contact hypersensi...
Corticotropin-releasing factor microinjection into the central nucleus of the amygdala alters REM sleep.
Psychological stressors have a prominent effect on rapid eye movement sleep (REMS) in humans and animals. We hypothesized that the stress-related neurochemical corticotropin-releasing factor (CRF), acting in the amygdala...
Effect of aniracetam on phosphatidylinositol transfer protein alpha in cytosolic and plasma membrane fractions of astrocytes subjected to simulated ischemia in vitro.
Brain ischemia affects phosphoinositide metabolism and the level of lipid-derived second messengers. Phosphatidylinositol transfer proteins (PI-PTs) are responsible for the transport of phosphatidylinositol (PI) and othe...
Role of nitric oxide in the development of tolerance to diazepam-induced motor impairment in mice.
Chronic treatment with the benzodiazepines is well known to produce tolerance, which has been extensively documented to be attributed to modifications in the gamma-aminobutyric acid (GABA)ergic neurotransmission. However...